Spots Global Cancer Trial Database for metastatic solid tumor
Every month we try and update this database with for metastatic solid tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | NCT06415487 | Locally Advance... Metastatic Soli... | Cyclophosphamid... Fludarabine ACE2016 Pembrolizumab | 18 Years - | Acepodia Biotech, Inc. | |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | NCT06440005 | Cancer Advanced Cancer Locally Advance... Metastatic Soli... Triple Negative... Pancreas Cancer Pancreatic Aden... | AGX101 | 18 Years - | Angiex, Inc. | |
| Study of ART6043 in Advanced/Metastatic Solid Tumors Patients | NCT05898399 | Advanced Solid ... Metastatic Soli... | ART6043 Olaparib Niraparib Olaparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | NCT04485013 | Cancer | TTX-080 TTX-080 pembrolizumab cetuximab | 18 Years - | Tizona Therapeutics, Inc | |
| The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors | NCT04614740 | Locally Advance... Metastatic Soli... | VC004 | 18 Years - | Jiangsu vcare pharmaceutical technology co., LTD | |
| The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies | NCT01393509 | Metastatic Soli... Lymphoma Myeloproliferat... | PU-H71 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| IL-2 PET Imaging in Advanced Solid Tumours | NCT05471271 | Metastatic Soli... | [18F]AlF-RESCA-... | 18 Years - | University Medical Center Groningen | |
| Subjects With Advanced or Metastatic Solid Tumor Malignancies | NCT05474859 | Metastatic Soli... Advanced Solid ... | XT-0528 | 18 Years - | Xenthera, Inc. | |
| A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers | NCT04761744 | DDR Gene Mutati... Metastatic Soli... | Nivolumab | 20 Years - | Korean Cancer Study Group | |
| A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors | NCT05824975 | Advanced Solid ... Metastatic Soli... | GI-102 GI-102 | 18 Years - | GI Innovation, Inc. | |
| A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors | NCT02133625 | Advanced Solid ... Metastatic Soli... | carboplatin pioglitazone | 18 Years - | Dana-Farber Cancer Institute | |
| Combination Therapy in Cancers With Mutations in DNA Repair Genes | NCT05694715 | Metastatic Soli... BRCA1 Mutation BRCA2 Mutation ATM Gene Mutati... PALB2 Gene Muta... | Niraparib Irinotecan | 18 Years - | University of California, San Francisco | |
| PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. | NCT05530200 | Metastatic Soli... | Hypofractionate... PD-L1 inhibitor GM-CSF IL-2 | 18 Years - | Second Affiliated Hospital of Soochow University | |
| A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab | NCT05259709 | Advanced Solid ... Metastatic Soli... | 89Zr˗DFO˗REGN50... cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) | NCT04003623 | Advanced or Met... FGFR Mutations FGFR Translocat... | Pemigatinib | 18 Years - | Incyte Corporation | |
| A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a | NCT00117013 | Neoplasms | Fluorine-19-Flu... Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity | NCT05809557 | Oncology Chemotherapeuti... Metastatic Soli... | Chemotherapy to... Oncology Consul... | 65 Years - | Masonic Cancer Center, University of Minnesota | |
| Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | NCT05863052 | Immune Checkpoi... Metastatic Soli... Nonsmall Cell L... Melanoma Renal Cell Carc... Gastrointestina... Squamous Cell C... | Immunotherapy | 18 Years - 99 Years | University of Oklahoma | |
| ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | NCT06415487 | Locally Advance... Metastatic Soli... | Cyclophosphamid... Fludarabine ACE2016 Pembrolizumab | 18 Years - | Acepodia Biotech, Inc. | |
| PraG With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid Tumors | NCT05435768 | Metastatic Soli... | Denosumab | 18 Years - | Second Affiliated Hospital of Soochow University | |
| Safety and Early Signs of Efficacy of IL12-L19L19. | NCT04471987 | Advanced Solid ... Metastatic Soli... | IL12-L19L19 IL12-L19L19 | 18 Years - 80 Years | Philogen S.p.A. | |
| Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors | NCT05279690 | Urothelial Canc... Metastatic Soli... | Colchicine | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 | NCT06235437 | Metastatic Soli... | ASD141 | 18 Years - | Ascendo Biotechnology Co., Ltd. | |
| A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients | NCT05828277 | Locally Advance... Metastatic Soli... | repotrectinib (... | 18 Years - | Turning Point Therapeutics, Inc. | |
| Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | NCT05856981 | Solid Tumor, Ad... Metastatic Soli... Refractory Canc... | ADU-1805 Pembrolizumab | 18 Years - | Sairopa B.V. | |
| Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors | NCT01302405 | Advanced Solid ... | PRI-724 | 18 Years - | Prism Pharma Co., Ltd. | |
| Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors | NCT01302405 | Advanced Solid ... | PRI-724 | 18 Years - | Prism Pharma Co., Ltd. | |
| A Study of KK2269 in Adult Participants With Solid Tumors | NCT06266299 | Advanced Solid ... Metastatic Soli... Gastric Adenoca... Gastroesophagea... Esophageal Aden... Non Small Cell ... | KK2269 Docetaxel | 18 Years - | Kyowa Kirin Co., Ltd. | |
| TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations | NCT04770246 | Advanced or Met... Advanced or Met... | TAS-117 TAS-117 TAS-117 TAS-117 | 12 Years - | Taiho Oncology, Inc. | |
| PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | NCT05639751 | Advanced Solid ... Metastatic Soli... Non-small Cell ... SMARCA4 Gene Mu... | PRT3789 Docetaxel | 18 Years - | Prelude Therapeutics | |
| A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors | NCT05983523 | Advanced Solid ... Metastatic Soli... | PEP07 | 20 Years - | PharmaEngine | |
| Safety and Early Signs of Efficacy of IL12-L19L19. | NCT04471987 | Advanced Solid ... Metastatic Soli... | IL12-L19L19 IL12-L19L19 | 18 Years - 80 Years | Philogen S.p.A. | |
| QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT04898543 | Metastatic Soli... | M-CENK, Suspens... N-803 (Cohort 2... Apheresis colle... | 18 Years - 100 Years | ImmunityBio, Inc. | |
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors | NCT05716295 | Advanced or Met... | MDK-703 Checkpoint Inhi... | 18 Years - 99 Years | Medikine, Inc. | |
| A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers | NCT04761744 | DDR Gene Mutati... Metastatic Soli... | Nivolumab | 20 Years - | Korean Cancer Study Group | |
| A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations | NCT05769075 | Locally Advance... Metastatic Soli... | TY-2136b TY-2136b | 18 Years - | TYK Medicines, Inc | |
| First-in-human Study of S-588210 (S-488210+S-488211) | NCT04316689 | Lung Cancer Head and Neck C... Bladder Cancer Esophageal Canc... Mesothelioma | S-488210 S-488211 | 18 Years - | Shionogi Inc. | |
| A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | NCT04801095 | Advanced Solid ... Metastatic Soli... Colorectal Canc... Lung Cancer Pancreatic Canc... Cholangiocarcin... Head and Neck C... | WM-S1-030 | 18 Years - | Wellmarker Bio | |
| IL-2 PET Imaging in Advanced Solid Tumours | NCT05471271 | Metastatic Soli... | [18F]AlF-RESCA-... | 18 Years - | University Medical Center Groningen | |
| Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | NCT05872867 | Advanced Solid ... Metastatic Soli... Lung Cancer Colorectal Canc... Pancreatic Canc... Cholangiocarcin... Head and Neck C... Non Small Cell ... | WM-A1-3389 Pembrolizumab | 19 Years - | Wellmarker Bio | |
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors | NCT05716295 | Advanced or Met... | MDK-703 Checkpoint Inhi... | 18 Years - 99 Years | Medikine, Inc. | |
| Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy | NCT04319198 | Metastatic Soli... | Sacituzumab Gov... | 18 Years - | Gilead Sciences | |
| A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | NCT05384626 | Locally Advance... Metastatic Soli... | NVL-655 | 12 Years - | Nuvalent Inc. | |
| Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies | NCT04294875 | Advanced Solid ... Metastatic Soli... | MPT0B640 | 18 Years - | J Ints Bio | |
| A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a | NCT00117013 | Neoplasms | Fluorine-19-Flu... Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors | NCT05983523 | Advanced Solid ... Metastatic Soli... | PEP07 | 20 Years - | PharmaEngine | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05867121 | Metastatic Soli... Non-small Cell ... Gastric Cancer Pancreatic Duct... | RO7496353 Atezolizumab Capecitabine S-1 Nivolumab Oxaliplatin Nab-paclitaxel Gemcitabine | 18 Years - | Genentech, Inc. | |
| Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | NCT06302621 | Advanced Solid ... Unresectable So... Metastatic Soli... Cholangiocarcin... | Afatinib Pemigatinib | 18 Years - | Massachusetts General Hospital | |
| A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours | NCT05717348 | Solid Tumor Locally Advance... Metastatic Soli... | ES014 | 18 Years - | Elpiscience (Suzhou) Biopharma, Ltd. | |
| Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | NCT05919537 | Non-Small Cell ... Pancreatic Canc... Locally Advance... Metastatic Soli... | HMBD-001 Docetaxel Nab-paclitaxel Gemcitabine | 18 Years - | Hummingbird Bioscience | |
| Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | NCT05856981 | Solid Tumor, Ad... Metastatic Soli... Refractory Canc... | ADU-1805 Pembrolizumab | 18 Years - | Sairopa B.V. | |
| A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies | NCT05028478 | Locally Advance... Metastatic Soli... Hematologic Mal... | CN202 | 18 Years - | Curon Biopharmaceutical (Australia) Co Pty Ltd | |
| Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies | NCT04294875 | Advanced Solid ... Metastatic Soli... | MPT0B640 | 18 Years - | J Ints Bio | |
| QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT04898543 | Metastatic Soli... | M-CENK, Suspens... N-803 (Cohort 2... Apheresis colle... | 18 Years - 100 Years | ImmunityBio, Inc. | |
| TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers | NCT04306900 | Solid Tumor, Ad... | TTX-030, budiga... TTX-030, budiga... TTX-030 and mFO... TTX-030 and bud... TTX-030, budiga... TTX-030 and pem... TTX-030, nab-pa... Budigalimab and... | 18 Years - 110 Years | Trishula Therapeutics, Inc. | |
| SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation | NCT05480865 | Solid Tumor, Ad... Metastatic Soli... Metastatic NSCL... Non Small Cell ... | BBP-398 sotorasib | 18 Years - 99 Years | Navire Pharma Inc., a BridgeBio company | |
| Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host | NCT00149032 | Hematological M... Neoplasm Metast... | DLI sensitized ... | - | Hadassah Medical Organization | |
| Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00323934 | Tumors Non Hodgkin's L... | MGCD0103 | 18 Years - | Mirati Therapeutics Inc. | |
| Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) | NCT04447651 | Metastatic Soli... SF3B1 Gene Muta... Spliceosome Mut... U2AF1 Gene Muta... SRSF2 Gene Muta... | Recommendation ... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | NCT05268666 | Locally Advance... Metastatic Soli... | JBI-802 | 18 Years - | Jubilant Therapeutics Inc. | |
| A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors | NCT04419532 | Solid Tumor Advanced Cancer Metastatic Soli... | DS-1055a | 18 Years - | Daiichi Sankyo | |
| Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | NCT05872867 | Advanced Solid ... Metastatic Soli... Lung Cancer Colorectal Canc... Pancreatic Canc... Cholangiocarcin... Head and Neck C... Non Small Cell ... | WM-A1-3389 Pembrolizumab | 19 Years - | Wellmarker Bio | |
| EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity | NCT05809557 | Oncology Chemotherapeuti... Metastatic Soli... | Chemotherapy to... Oncology Consul... | 65 Years - | Masonic Cancer Center, University of Minnesota | |
| First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | NCT05277051 | Neoplasms | GSK4381562 Dostarlimab GSK4428859A | 18 Years - | GlaxoSmithKline | |
| The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors | NCT04614740 | Locally Advance... Metastatic Soli... | VC004 | 18 Years - | Jiangsu vcare pharmaceutical technology co., LTD | |
| A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors | NCT05935098 | Advanced Solid ... Metastatic Soli... Solid Tumor | BGB-A3055 Tislelizumab | 18 Years - | BeiGene | |
| Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors | NCT00997529 | Metastatic Soli... | nonmyeloablativ... | 18 Years - 60 Years | Beth Israel Deaconess Medical Center | |
| HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors | NCT03284502 | Locally Advance... Metastatic Soli... | HM95573, cobime... HM95573, cetuxi... HM95573, cobime... HM95573, cetuxi... | 19 Years - | Hanmi Pharmaceutical Company Limited | |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | NCT04579757 | Metastatic Soli... Colorectal Canc... Neuroendocrine ... Small Cell Lung... Gastric Cancer Soft Tissue Sar... Anaplastic Thyr... | Surufatinib and... Surufatinib and... | 18 Years - | Hutchmed | |
| A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer | NCT04474470 | Solid Tumor, Ad... Squamous Cell C... Colorectal Aden... Metastatic Soli... Recurrent Solid... Head and Neck C... | NT219 NT219 and ERBIT... NT219 and ERBIT... | 18 Years - | Purple Biotech Ltd. | |
| A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas | NCT04986865 | Advanced Solid ... Metastatic Soli... Mature B-cell N... | ATG-101 | 18 Years - | Antengene Corporation | |
| A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations | NCT05769075 | Locally Advance... Metastatic Soli... | TY-2136b TY-2136b | 18 Years - | TYK Medicines, Inc | |
| LAG3 PET Imaging in Advanced Solid Tumors | NCT04706715 | Metastatic Soli... | 89Zr-DFO-REGN37... Cemiplimab | 18 Years - | University Medical Center Groningen | |
| Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy | NCT04393454 | Metastatic dMMR... Solid Tumor Cancer Metastatic Soli... | Sirolimus 2Mg T... | 18 Years - 65 Years | Albert Einstein College of Medicine | |
| A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | NCT05118789 | Locally Advance... Metastatic Soli... | NVL-520 | 12 Years - | Nuvalent Inc. | |
| A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors | NCT06244771 | Advanced Solid ... Solid Tumor, Ad... Unresectable So... Metastatic Soli... Non Small Cell ... Colorectal Canc... KRAS G12C Pancreatic Canc... | FMC-376 | 18 Years - | Frontier Medicines Corporation | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors | NCT05169437 | Solid Tumor Breast Tumor Colon Tumor, Ma... Lung Tumor Urologic Cancer Pancreatic Canc... Melanoma Metastatic Canc... Locally Advance... Esophageal Canc... Endometrial Can... Head and Neck C... | Niraparib | 18 Years - | Tempus AI | |
| Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05520099 | Colorectal Canc... Head and Neck S... Non Small Cell ... Cutaneous Melan... Endometrial Can... Urothelial Carc... Clear Cell Rena... | Core Needle or ... | 18 Years - | Elephas | |
| A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | NCT06270706 | Metastatic Soli... | PLN-101095 Pembrolizumab | 18 Years - | Pliant Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
